Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia.

Détails

ID Serval
serval:BIB_2AC50692D49C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia.
Périodique
Journal of Pediatric Hematology/Oncology
Auteur⸱e⸱s
Fattet S., Cassinotti P., Popovic M.B.
ISSN
1077-4114
Statut éditorial
Publié
Date de publication
2004
Peer-reviewed
Oui
Volume
26
Numéro
8
Pages
497-503
Langue
anglais
Résumé
OBJECTIVE: To report on B19 infection management and chemotherapy schedule consequences in five children treated for acute lymphocytic leukemia (ALL). PATIENTS AND METHODS: Between May 2001 and February 2002, five patients between 4 and 12 years of age, receiving maintenance chemotherapy for ALL, presented with symptoms suggesting B19 infection (pallor, fatigue, petechiae and pancytopenia in four patients; generalized rash in two patients; acute hepatitis in one patient). Qualitative polymerase chain reaction (PCR) on peripheral blood was used for diagnosis and follow-up of infection; quantitative PCR was used for viral load measurement. Intravenous nonspecific high-dose immunoglobulin therapy was administered until PCR was negative. RESULTS: Qualitative B19 DNA was found in the peripheral blood of all patients, confirming the infection. Viral load at diagnosis ranged from 10 to 10 particles/mL blood. B19 DNA was detectable in four patients at 45, 21, 40, and 44 weeks, respectively. Chemotherapy was delayed in all patients. No clear benefit of intravenous immunoglobulin was noted. CONCLUSIONS: Infection with B19 is rarely reported in patients with ALL, but it should be suspected when unexplained pancytopenia occurs during chemotherapy. Persistent B19 infection remains a challenge in the management of patients receiving maintenance chemotherapy for ALL, as no specific therapy such as a specific immunoglobulin or vaccine exists. The role of viral load measurement needs to be established in terms of its use in follow-up and evaluation of the therapeutic response.
Mots-clé
Antineoplastic Agents, Child, Child, Preschool, DNA, Viral, Erythema Infectiosum, Female, Humans, Immunocompromised Host, Immunoglobulins, Intravenous, Male, Parvovirus B19, Human, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pubmed
Web of science
Création de la notice
20/03/2008 9:34
Dernière modification de la notice
20/08/2019 13:10
Données d'usage